Sentences with phrase «program in a corporate environment»

Would you like to learn more about how to develop effective testing for your online training program in a corporate environment?

Not exact matches

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tprograms; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tPrograms (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tprograms; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

Strong candidates will have 1 - 3 years of consulting, M&A, strategy, or corporate development experience out of a first - tier undergraduate program and find intrinsic reward in an unstructured environment where individuals define their roles, own their actions and have outsized impact.

The program is designed to «make nursing OK in a corporate environment,» Cohen says.

There are huge opportunities for Eating Psychology Coaches to work together with businesses to plan and implement programs focusing on Mind Body Nutrition right in the corporate environment.

Traditional learning environments in the education sector are rapidly being replaced by eLearning programs in the corporate sector, driven by the need for brisk professional growth.

TYPE & AMOUNT OF EXPERIENCE: • Bachelor's degree and 5 years of designing, developing, and facilitating blended learning programs • Experience in creating engaging and innovative eLearning content across a range of topics • Experience in needs assessment, visual design, storyboarding and script design • Experience working in a corporate environment

Students enrolling in the Master's of Education online degree program will get a glimpse of what education will look like to future generations of students; from classrooms to corporate environments to military training facilities and beyond.

Under his leadership, the organization solidified its position in a rapidly changing media environment as Knell leveragedNPR's network of member stations, drove cross-platform journalism and cultural programming, and grew philanthropic and corporate underwriting support.

February 2, 1984 report from Andrew J. Callegari on Exxon Corporate Research Program to provide Exxon with a source of expertise in an area which could have a major impact on the future business environment, and contribute to a broad scientific investigation of CO2 effects.

Snyder — American by origin, based in Europe since 1995, and licensed to practice in Illinois, New York and Paris with 20 years» experience in international corporate law — credits a summer program in 21st century law with kindling her fascination with the United Kingdom's regulatory environment for legal services.

«If you believe that Windows 10 will be used in the corporate environment, and you believe that corporate wellness programs will begin to proliferate — employees being rewarded for being fit — this makes a great deal of sense,» she told TechNewsWorld.

Soft Skills Trainers are often found in corporate environments and are responsible for implementing training programs, assessing trainee needs, evaluating results, and offering advice to program beneficiaries.

Professional Trainers provide training services, usually in corporate environments, and design effective training programs.

SUMMARY Seeking to leverage my Program, Product and Project Management background in a: start - up, expansion or growing corporate environment for the creation, development and / or migration of the product or solution.

Globally competent, focused, and seasoned professional with extensive, accomplishment - laden experience in IT systems and program management under large, diverse corporate environment.

Qualifications * Twenty year experience as an IT Professional in areas of Technical Support, System Engineering, Application Programming and Network Administration in both government and highly diverse corporate environments.

As a corporate director, manage compliance programs that encompass education, skills, and experience in health, safety, and the environment.

IT Leadership - PMO and Project / Portfolio / Change / Application Portfolio Management Assigned to an IT program manager role for management of a six company subsidiary integration to form NTT DATA Re-framed and subsequently instituting a portfolio governance practices via a functional representative - based operating committee Re-formed the Corporate IT PMO practices within a multi-geography team environment Analyzed and developed a turn - around roadmap to address fundamental weakness in our internal delivery capability in partnership with both the PM staff members, as well as our stakeholders.

Professional Duties & Responsibilities Directed operations of Target Stores generating $ 20 million in annual revenue Created and implemented strategies to cut expenses while increasing sales Assisted corporate leadership with store marketing and branding efforts Hired, trained, managed, and reviewed more than 130 team members Enhanced employee value through professional development programs Increased employee dedication through recognition and team building initiatives Managed logistics team operations including product unloading and stocking Oversaw planogram, pricing, instocks, backroom, and replenishment teams Created an attractive and impactful salesfloor ensuring steady sales Coordinated all salesfloor transitions, salesplanner, signage, and pricing sets Ensured the highest levels of customer service resulting in repeat business Served as liaison between Target leadership and construction contractors Guaranteed store safety, security, and branding during remodel Built strong, long - term relationships with business partners, coworkers, and employers Completed all duties in a positive, professional, and timely manner Fostered an environment of respect and dedication to company goals

Director of Cardiopulmonary Services — Duties & Responsibilities Direct and evaluate cardiopulmonary department and personnel ensuring effective and profitable operations Recruit and train staff in hospital policies, procedures, best practices, and corporate branding Increase gross revenue from $ 540,000 to $ 3.9 million in 6 years through marketing and management initiatives Set and strictly adhere to departmental budgets and schedules Utilize strong management experience to drive operations in an efficient and professional manner Proven ability to handle multiple projects in fast paced, high pressure environments Responsible for project conception, analysis, development, and launch Develop and implement pulmonary function lab with stress pulmonary functionality, nuclear stress testing program, CPOE, and cardiopulmonary rehabilitation program Design and launch successful marketing strategy for Sleep Lab including all collateral materials Proficient in industry applicable software including Word, Excel, Power Point, Pac's, CPSI, and All Scripts Build and strengthen professional relationship with community leaders, coworkers, and industry figures Represent company with poise, integrity, and positivity